TELA
TELA Bio, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.82
+5.19%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
Market Cap
$36.88M
MomentumView details →
1D Return
+5.19%
YTD Return
−30.51%
RSI (14)
59.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
Market Cap
$36.88M
RSI (14)
59.4
MomentumView details →
1D Return
+5.19%
YTD Return
−30.51%
SummaryUpdated Jun 1, 2026
TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company founded in 2012 and headquartered in Malvern, Pennsylvania. The company went public in November 2019 and specializes in developing and commercializing soft-tissue reconstruction solutions for hernia repair and plastic surgery applications. TELA Bio focuses on providing alternatives to traditional synthetic mesh products by offering reinforced tissue matrices derived from natural ovine (sheep) tissue combined with synthetic materials to optimize patient outcomes while preserving anatomical integrity.
Similar companies
Latest newsMore news →
Heather Getz was appointed principal financial officer of TELA Bio, Inc., effective August 31, 2026.5d agoTELA Bio announced a transition in its Chief Operating Officer and Chief Financial Officer roles.5d agoTELA Bio announced a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million or 18%.5d ago